Advertisement

Search Results

Advertisement



Your search for Sarat Chandarlapaty, MD, PhD matches 5 pages

Showing 1 - 5


breast cancer

Trastuzumab Emtansine in Treatment of Residual Breast Cancer After Neoadjuvant Therapy: Who Will Benefit?

The discovery of trastuzumab has been revolutionary in the treatment of HER2-positive breast cancer, both in the metastatic and early-stage settings.1-6 This cannot be disputed. In the early-stage setting, the addition of trastuzumab to standard chemotherapy has led to a 50% gain in...

Highlights From the Conquer Cancer Foundation’s Third Annual Career Development Retreat

The Conquer Cancer Foundation of ASCO is committed to supporting the research and career development of young researchers through its Grants & Awards Program. In October 2017, Conquer Cancer hosted its third Scientific and Career Development Retreat at ASCO Headquarters in Alexandria,...

breast cancer

Prevalence of Estrogen Receptor Mutations in Patients With Metastatic Breast Cancer

A new study published online by JAMA Oncology examined the prevalence and significance of estrogen receptor mutations in patients with metastatic breast cancer.1 The activation of the estrogen receptor is a feature of most breast cancers in which estrogen receptor expression is detected. An...

breast cancer

Sarat Chandarlapaty, MD, PhD, on BOLERO-2 Clinical Trial Results

Sarat Chandarlapaty, MD, PhD, of the Memorial Sloan Kettering Cancer Center, discusses results from this study that showed patients with ER-positive metastatic breast cancer who had a D538G and/or a Y537S mutation in the ESR1 gene had significantly worse median overall survival (Abstract S2-07).

breast cancer
issues in oncology

SABCS 2015: ESR1 Gene Mutations Are Associated With Worse Overall Survival in Metastatic ER-Positive Breast Cancer

A study by Chandarlapaty et al investigating whether mutations in the estrogen receptor are common in patients with advanced breast cancer and how they affect patient outcomes has found that the D538G and Y537S mutations in the estrogen receptor 1 (ESR1) gene are prevalent in patients with advanced ...

Advertisement

Advertisement



Advertisement